Merck will split into two companies

On February 5, MSD released its Q4 and full year financial report in 2019, and announced a major news that it has decided to split MSD into two growth companies! MSD said it would spin off the franchises of women's health, patent brands and bio similar drugs and set up an independent listed company Kenneth C Frazier, chairman and CEO of MSD, announced the news, saying that by optimizing MSD's human health product portfolio, MSD could be closer to the company's goal of becoming a leading R & D-based biopharmaceutical company In today's financial report, we can see that in 2019, the annual sales of MSD reached 46.8 billion US dollars, of which the annual sales of keytruda, a heavy product in the field of cancer, reached 11.1 billion US dollars, an increase of 55% Mosadon said that the two companies after the split can better meet the needs of patients and improve global public health Among them, mosadon will continue to move forward to become a leading R & D biopharmaceutical company, focusing on the current growth pillar product areas: tumor, vaccine, hospital products, animal health care The spin off of the new company will explore potential in the areas of women's health, over patented brands and bioequivalent drugs, especially in the areas of fertility and contraception, and pursue global leadership and sustainable growth.